EA201591409A1 - Бициклические соединения - Google Patents

Бициклические соединения

Info

Publication number
EA201591409A1
EA201591409A1 EA201591409A EA201591409A EA201591409A1 EA 201591409 A1 EA201591409 A1 EA 201591409A1 EA 201591409 A EA201591409 A EA 201591409A EA 201591409 A EA201591409 A EA 201591409A EA 201591409 A1 EA201591409 A1 EA 201591409A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
bicyclic compounds
diseases
slowing
progression
Prior art date
Application number
EA201591409A
Other languages
English (en)
Other versions
EA025294B1 (ru
Inventor
Т. Г. Мурали Дхар
Хай-Юнь Сяо
Аларик Дж. Дикман
Эрик Дж. Чан
Марта Даброс
Дэниэл Ричард Робертс
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201591409A1 publication Critical patent/EA201591409A1/ru
Publication of EA025294B1 publication Critical patent/EA025294B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Описаны соединения формулы (I)и/или их соль; где R представляет собой -ОН или -ОР(О)(ОН). Также описаны способы применения таких соединений в качестве селективных агонистов в отношении сопряженного с G-белком рецептора S1Pи содержащие такие соединения фармацевтические композиции. Указанные соединения применимы в лечении, профилактике или замедлении прогрессирования заболеваний или нарушений в таких разнообразных терапевтических областях, как аутоиммунные заболевания и сосудистое заболевание.
EA201591409A 2013-02-21 2014-02-21 Бициклические соединения в качестве модуляторов активности сопряженного с g-белком рецептора s1p EA025294B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (en) 2013-02-21 2014-02-21 Bicyclic compounds

Publications (2)

Publication Number Publication Date
EA201591409A1 true EA201591409A1 (ru) 2015-12-30
EA025294B1 EA025294B1 (ru) 2016-12-30

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591409A EA025294B1 (ru) 2013-02-21 2014-02-21 Бициклические соединения в качестве модуляторов активности сопряженного с g-белком рецептора s1p

Country Status (35)

Country Link
US (3) US9115054B2 (ru)
EP (1) EP2958888B1 (ru)
JP (1) JP6277210B2 (ru)
KR (1) KR102242265B1 (ru)
CN (1) CN105026362B (ru)
AR (1) AR094851A1 (ru)
AU (1) AU2014218883B2 (ru)
BR (1) BR112015019919A2 (ru)
CA (1) CA2902168C (ru)
CL (1) CL2015002358A1 (ru)
CY (1) CY1118641T1 (ru)
DK (1) DK2958888T3 (ru)
EA (1) EA025294B1 (ru)
ES (1) ES2613262T3 (ru)
HK (1) HK1218111A1 (ru)
HR (1) HRP20170247T1 (ru)
HU (1) HUE031626T2 (ru)
IL (1) IL240613B (ru)
LT (1) LT2958888T (ru)
MA (1) MA38425B1 (ru)
MX (1) MX2015010347A (ru)
MY (1) MY173990A (ru)
PE (1) PE20151746A1 (ru)
PH (1) PH12015501793A1 (ru)
PL (1) PL2958888T3 (ru)
PT (1) PT2958888T (ru)
RS (1) RS55703B1 (ru)
SG (1) SG11201506408TA (ru)
SI (1) SI2958888T1 (ru)
SM (1) SMT201700115B (ru)
TN (1) TN2015000356A1 (ru)
TW (1) TWI613182B (ru)
UY (1) UY35338A (ru)
WO (1) WO2014130752A2 (ru)
ZA (1) ZA201506965B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6617702B2 (ja) 2013-07-15 2019-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｆｔｙ７２０のアザサイクリック拘束アナログ
AR101591A1 (es) * 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
WO2017053990A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
KR102482825B1 (ko) 2016-09-02 2022-12-29 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2006088944A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
AU2006245438A1 (en) 2005-02-18 2006-11-16 Bellus Health (Innodia) Inc. Analogs of 4-hydroxyisoleucine and uses thereof
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
PL1863474T3 (pl) 2005-03-23 2009-04-30 Actelion Pharmaceuticals Ltd Nowe pochodne tiofenu jako agoniści receptora 1 1-fosforanu sfingozyny
WO2006115188A1 (ja) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
CA2610310A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
BRPI0615133A2 (pt) 2005-08-23 2011-05-03 Irm Llc compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
RU2008134702A (ru) 2006-01-27 2010-03-10 Юниверсити Оф Вирждиния Пэтент Фаундейшн (Us) Способ лечения невропатической боли
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
EP2010524A2 (en) 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
PL2069335T3 (pl) 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
CA2672727A1 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
RU2473545C2 (ru) 2007-02-02 2013-01-27 Ф.Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
AU2008320374A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
EP2280933B1 (en) 2008-04-01 2013-07-24 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
WO2010069949A1 (en) 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
CN102361867A (zh) 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
JP2012515788A (ja) * 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
EP2395986A1 (en) 2009-02-10 2011-12-21 Abbott Laboratories Methods for preparing s1p receptor agonists and antagonists
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
MX336881B (es) 2009-10-29 2016-02-04 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos.
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
EP2595969B1 (en) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
CN103237795B (zh) 2010-09-24 2015-10-21 百时美施贵宝公司 经取代的噁二唑化合物及其作为s1p1激动剂的用途
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
EP2685971A4 (en) 2011-03-18 2014-01-22 Univ Virginia Patent Found COMPOSITIONS AND METHODS FOR TISSUE PROCESSING AND CELL-BASED THERAPIES
EP2541155B1 (en) 2011-04-26 2016-02-24 Panasonic Intellectual Property Management Co., Ltd. Heating system, and heating system control method
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
JP6324380B2 (ja) 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物

Also Published As

Publication number Publication date
US9115054B2 (en) 2015-08-25
CY1118641T1 (el) 2017-07-12
BR112015019919A2 (pt) 2017-07-18
DK2958888T3 (en) 2017-03-06
MA38425A1 (fr) 2017-12-29
US20140235591A1 (en) 2014-08-21
US9359286B2 (en) 2016-06-07
EP2958888B1 (en) 2016-11-23
SMT201700115B (it) 2017-03-08
TN2015000356A1 (en) 2017-01-03
SI2958888T1 (sl) 2017-01-31
WO2014130752A3 (en) 2014-10-23
RS55703B1 (sr) 2017-07-31
EP2958888A2 (en) 2015-12-30
KR20150119352A (ko) 2015-10-23
PT2958888T (pt) 2017-02-03
SG11201506408TA (en) 2015-09-29
MA38425B1 (fr) 2019-03-29
ES2613262T3 (es) 2017-05-23
PH12015501793B1 (en) 2015-11-09
CL2015002358A1 (es) 2016-02-26
EA025294B1 (ru) 2016-12-30
AR094851A1 (es) 2015-09-02
MX2015010347A (es) 2015-11-16
US9487481B2 (en) 2016-11-08
HK1218111A1 (zh) 2017-02-03
LT2958888T (lt) 2017-02-10
JP6277210B2 (ja) 2018-02-07
IL240613B (en) 2018-06-28
HUE031626T2 (en) 2017-07-28
AU2014218883B2 (en) 2017-05-11
US20150315128A1 (en) 2015-11-05
PE20151746A1 (es) 2015-12-02
CA2902168C (en) 2019-01-08
IL240613A0 (en) 2015-10-29
TW201444786A (zh) 2014-12-01
PL2958888T3 (pl) 2017-07-31
US20160251309A1 (en) 2016-09-01
AU2014218883A1 (en) 2015-10-15
ZA201506965B (en) 2017-08-30
UY35338A (es) 2014-08-29
HRP20170247T1 (hr) 2017-04-07
WO2014130752A2 (en) 2014-08-28
KR102242265B1 (ko) 2021-04-19
JP2016513124A (ja) 2016-05-12
CA2902168A1 (en) 2014-08-28
MY173990A (en) 2020-03-03
PH12015501793A1 (en) 2015-11-09
CN105026362B (zh) 2017-07-14
TWI613182B (zh) 2018-02-01
CN105026362A (zh) 2015-11-04

Similar Documents

Publication Publication Date Title
EA201591409A1 (ru) Бициклические соединения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790427A1 (ru) Замещенные бициклические соединения
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201790745A1 (ru) Трициклические соединения
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201891710A1 (ru) Терапевтические соединения
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU